The Pharmacy Times® Pharmacy Hospital Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to hospital and health-system pharmacists.
April 27th 2025
Zoldonrasib, a novel oral KRAS G12D-selective inhibitor, demonstrated promising safety and early antitumor activity in patients with previously treated non–small cell lung cancer (NSCLC), offering a potential new targeted therapy for this underserved population.
SGO 2025: The MRI Gap and How Race and Insurance Shape Cervical Cancer Treatment Timelines
April 8th 2025Sophie Jabban discusses research presented at the SGO Annual Meeting highlighting significant disparities in MRI access for patients with cervical cancer receiving chemoradiation, with delays linked to both race and insurance status, underscoring systemic barriers that may impact timely treatment.
Read More
AAN 2025: Intracerebral Hemorrhage Treatment Requires Proactive Approach, Pharmacist Involvement
April 8th 2025Kara Melmed, MD, emphasizes the critical importance of rapid, team-based intervention for intracerebral hemorrhage (ICH) patients, with pharmacists playing a key role in blood pressure management.
Watch
Long-Term Tirzepatide Demonstrates Benefits in Patients With CKD, Obesity, and HFpEF
April 7th 2025Tirzepatide-treated patients with chronic kidney disease (CKD), obesity, and heart failure with preserved ejection fraction (HFpEF) had improved renal function both by cystatin C and creatinine.
Read More
Rilzabrutinib Granted Orphan Drug Designation For Multiple Rare, Immune-Mediated Conditions
April 4th 2025The new designations span both warm autoimmune hemolytic anemia and IgG4-related disease, 2 rare, immune-mediated conditions that burden patients due to a lack of available treatment options.
Read More
FDA Grants Accelerated Approval to Atrasentan for Proteinuria Reduction in Primary IgA Nephropathy
April 3rd 2025Positive results from an interim analysis of the phase 3 ALIGN study bolstered atrasentan towards receiving accelerated approval for patients with immunoglobulin A nephropathy, a rare condition that can cause kidney failure.
Read More
Revolutionizing Treatment with Bispecific Therapies: Navigating the Challenges Ahead
April 2nd 2025By decade’s end, approval of additional bispecifics is expected for hematological malignancies, solid tumors, and non-oncology conditions such as inflammatory, autoimmune, neurodegenerative and vascular diseases, and ocular disorders and infections.
Read More